Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins
- 22 August 2001
- Vol. 27 (6) , 652-655
- https://doi.org/10.1016/s0305-4179(01)00005-5
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- A case of toxic epidermal necrolysis treated with intravenous immunoglobulinBritish Journal of Dermatology, 2000
- Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis?Intensive Care Medicine, 1999
- Fas Ligand: A Sensor for DNA Damage Critical in Skin Cancer EtiologyScience, 1999
- Would Cyclosporin A Be Beneficial to Mitigate Drug-Induced Toxic Epidermal Necrolysis?Dermatology, 1999
- Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysisThe Lancet, 1998
- Fas ligand is expressed in normal skin and in some cutaneous malignanciesBritish Journal of Dermatology, 1998
- Toxic epidermal necrolysisThe Lancet, 1998
- Fas–FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunityImmunology Today, 1998
- Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.Journal of Clinical Investigation, 1997
- Distribution of apoptosis-mediating Fas antigen in human skin and effects of anti-Fas monoclonal antibody on human epidermal keratinocyte and squamous cell carcinoma cell linesArchives of Dermatological Research, 1994